Introducing the "Rare Disease Drug Development Series: What Patients and Advocates Need to Know."
Patients and caregivers are vital contributors in the research and development process of treatments for all diseases and disorders. This is especially true for rare diseases: when patient populations are smaller than 200,000 people—sometimes much smaller—the need for individuals to act as proactive partners to the research community is greater. To do that effectively, patients and patient advocacy organizations need to understand the drug development process inside and out.
The National Organization for Rare Disorders (NORD) has created a free online course in collaboration with the FDA’s Center for Drug Evaluation and Research (CDER) and the Critical Path Institute (C-Path), designed to help patients, caregivers, and patient advocacy groups understand the drug development process so we can produce more and better treatments for rare diseases.
Start learning today at learn.rarediseases.org
